Targeting metabolic vulnerability of tumor cells is a promising anticancer strategy. However, the therapeutic efficacy of existing metabolism‐regulating agents is often compromised due to tolerance resulting from tumor metabolic plasticity, as well as their poor bioavailability and tumor‐targetability. Inspired by the inhibitive effect of N‐ethylmaleimide on the mitochondrial function, a dendronized‐polymer‐functionalized metal‐phenolic nanomedicine (pOEG‐b‐D‐SH@NP) encapsulating maleimide‐modified doxorubicin (Mal‐DOX) is developed to enable improvement in the overall delivery efficiency and inhibition of the tumor metabolism via multiple pathways. It is observed that Mal‐DOX and its derived nanomedicine induces energy depletion of CT26 colorectal cancer cells more efficiently than doxorubicin, and shifts the balance of programmed cell death from apoptosis toward necroptosis. Notably, pOEG‐b‐D‐SH@NP simultaneously inhibits cellular oxidative phosphorylation and glycolysis, thus potently suppressing cancer growth and peritoneal intestinal metastasis in mouse models. Overall, the study provides a promising dendronized‐polymer‐derived nanoplatform for the treatment of cancers through impairing metabolic plasticity.
Impairing Tumor Metabolic Plasticity via a Stable Metal‐Phenolic‐Based Polymeric Nanomedicine to Suppress Colorectal Cancer
Xiaoling Li,Zhenyu Duan,Xiaoting Chen,Dayi Pan,Qiang Luo,Lei Gu,Gang Xu,Yinggang Li,Hu Zhang,Qiyong Gong,Rongjun Chen,Zhongwei Gu,Kui Luo
Published 2023 in Advances in Materials
ABSTRACT
PUBLICATION RECORD
- Publication year
2023
- Venue
Advances in Materials
- Publication date
2023-03-14
- Fields of study
Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-56 of 56 references · Page 1 of 1
CITED BY
Showing 1-93 of 93 citing papers · Page 1 of 1